within Pharmacolibrary.Drugs.ATC.M;

model M01CC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01CC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bucillamine is a disease-modifying antirheumatic drug (DMARD) structurally related to D-penicillamine. It is primarily used in Japan and South Korea for the treatment of rheumatoid arthritis and is not approved in most other countries. Bucillamine exerts anti-inflammatory and immunomodulatory effects, serving as a thiol donor with antioxidant properties.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult population, oral administration, based on analogies with D-penicillamine and available clinical summaries in Japanese prescribing information sources. No direct publication of detailed PK parameter values was found in the literature.</p><h4>References</h4><ol><li><p>Horwitz, LD (2003). Bucillamine: a potent thiol donor with multiple clinical applications. <i>Cardiovascular drug reviews</i> 21(2) 77–90. DOI:<a href=\"https://doi.org/10.1111/j.1527-3466.2003.tb00107.x\">10.1111/j.1527-3466.2003.tb00107.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12847560/\">https://pubmed.ncbi.nlm.nih.gov/12847560</a></p></li><li><p>Yanagi, Y, et al., &amp; Mano, H (2002). Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. <i>Investigative ophthalmology &amp; visual science</i> 43(11) 3495–3499. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12407161/\">https://pubmed.ncbi.nlm.nih.gov/12407161</a></p></li><li><p>Lee, KC, et al., &amp; Youn, YS (2009). Development and validation of a reversed-phase fluorescence HPLC method for determination of bucillamine in human plasma using pre-column derivatization with monobromobimane. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 877(22) 2130–2134. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2009.06.010\">10.1016/j.jchromb.2009.06.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19546034/\">https://pubmed.ncbi.nlm.nih.gov/19546034</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01CC02;
